INNOCARE (688428.SH) is expected to increase its revenue by about 37% in 2024, with a net loss of approximately 443 million yuan.
Nuo Chen Jianhua (688428.SH) announced that the company expects to achieve revenue of RMB 1 billion from Obutini in 2024.
INNOCARE (688428.SH) announced that the company expects the revenue of Obutini to reach approximately 1.001 billion yuan in 2024, an increase of around 49% compared to the same period last year. The total operating revenue is expected to be around 1.01 billion yuan, a growth of about 37% compared to the same period last year.
The net profit attributable to the owners of the parent company is expected to be around -443 million yuan, a decrease of approximately 30% compared to the same period last year. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be around -444 million yuan, a decrease of about 29% compared to the same period last year.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025